- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Role of Crizotinib in previously treated non-small-cell lung cancer ; volume:03 ; number:02 ; year:2014 ; pages:138-140
South Asian journal of cancer ; 03, Heft 02 (2014), 138-140
- Beteiligte Personen und Organisationen
-
Gupta, Sunil Kumar
- DOI
-
10.4103/2278-330X.130468
- URN
-
urn:nbn:de:101:1-2021022619312245515608
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:25 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Gupta, Sunil Kumar
Ähnliche Objekte (12)
Non-small-cell lung cancer
Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England
Pharmacometric applications in non-small-cell lung cancer
Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer
Gefitinib (Iressa, ZD 1839) A Potential Chemotherapy Sensitizer in Previously Chemotherapy Nonresponded Advanced Non-Small-Cell Lung Cancer Patients
Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer
Two-year survival with nivolumab in previously treated advanced non–small-cell lung cancer: a real-world pooled analysis of patients from France, Germany, and Canada
FDG-PET radiomics for response monitoring in non-small-cell lung cancer treated with radiation therapy
Perioperative immunotherapy for resectable non-small-cell lung cancer
Clusterin modulates transdifferentiation of non-small-cell lung cancer
Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer
First-Line Immunotherapy in Advanced Non-Small-Cell Lung Cancer
Non-small-cell lung cancer
Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England
Pharmacometric applications in non-small-cell lung cancer
Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer
Gefitinib (Iressa, ZD 1839) A Potential Chemotherapy Sensitizer in Previously Chemotherapy Nonresponded Advanced Non-Small-Cell Lung Cancer Patients
Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer
Two-year survival with nivolumab in previously treated advanced non–small-cell lung cancer: a real-world pooled analysis of patients from France, Germany, and Canada
FDG-PET radiomics for response monitoring in non-small-cell lung cancer treated with radiation therapy
Perioperative immunotherapy for resectable non-small-cell lung cancer
Clusterin modulates transdifferentiation of non-small-cell lung cancer
Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer
First-Line Immunotherapy in Advanced Non-Small-Cell Lung Cancer
Non-small-cell lung cancer
Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England
Pharmacometric applications in non-small-cell lung cancer
Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer
Gefitinib (Iressa, ZD 1839) A Potential Chemotherapy Sensitizer in Previously Chemotherapy Nonresponded Advanced Non-Small-Cell Lung Cancer Patients
Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer
Two-year survival with nivolumab in previously treated advanced non–small-cell lung cancer: a real-world pooled analysis of patients from France, Germany, and Canada
FDG-PET radiomics for response monitoring in non-small-cell lung cancer treated with radiation therapy
Perioperative immunotherapy for resectable non-small-cell lung cancer
Clusterin modulates transdifferentiation of non-small-cell lung cancer
Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer